The health sector is witnessing crucial developments including US turkey flu testing advocacy, WHO lobbying to retain US membership, and Medicare price negotiations involving major drugs. Meanwhile, ...
The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...
DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...
Medicare seeks to negotiate prices on 15 drugs, including Novo Nordisk's (NVO) GLP-1 weight-loss drugs Ozempic and Wegovy, in ...
Current health news highlights include debates over Medicare pricing for drugs like Ozempic and Wegovy, management shifts ...
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback